English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The purpose of this study was to evaluate the potential of 16α- 18 F-fluoro-17β-estradiol ( 18 F-FES) PET to predict prognosis in patients with endometrial cancer (EC). Methods: In total, 67 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-IV EC underwent 18 F-FES and 18 F-FDG PET/CT before treatment. The SUV mean of the primary tumor was compared with the clinical characteristics, and the relationships between SUV and progression-free survival (PFS) or overall survival were analyzed. Results:  18 F-FES SUV was significantly associated with stage, histology, lymphovascular space involvement (LVSI), and lymph node metastasis, and 18 F-FDG SUV was significantly associated with stage, myometrial invasion, tumor size, and lymph node metastasis. Receiver-operating characteristic curve analysis revealed that 18 F-FES SUV could significantly detect tumor progression and survival, with areas under the curve of 0.813 and 0.790, respectively, whereas 18 F-FDG SUV could detect them with areas under the curve of 0.557 and 0.635, respectively. The Kaplan-Meier survival curve showed that patients with a low 18 F-FES SUV had significantly poor PFS ( P &lt; 0.001) and overall survival ( P = 0.001) compared with patients with a high SUV, whereas 18 F-FDG showed no significant differences. In a subanalysis of 27 patients with a low risk of recurrence (FIGO stage IA endometrioid carcinoma [grade 1 or 2] without LVSI), those with a low 18 F-FES SUV also had poorer PFS than those with a high SUV ( P = 0.002). In multivariate analysis, an 18 F-FES SUV of less than 2.63 ( P = 0.037; hazard ratio, 10.727; 95% CI, 1.16-99.35) and FIGO stages III and IV ( P = 0.042; hazard ratio, 8.838; 95% CI, 1.09-71.84) were significantly associated with PFS. Conclusion: A low 18 F-FES for the primary tumor was strongly associated with prognostic factors of EC such as LVSI and lymph node metastasis, and a low 18 F-FES SUV was an independent prognostic factor for PFS in patients with EC. These data suggest that pretreatment 18 F-FES PET might be useful in determining the appropriate treatment for patients with EC.

Prognostic Value of 16α-18F-Fluoro-17β-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study

Prognostic Value of 16α-¹⁸F-Fluoro-17β-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study